Endo Accused Of Antitrust Pay-For-Delay Schemes
This article was originally published in Scrip
Executive Summary
Endo International PLC became the latest target of the US Federal Trade Commission (FTC) in the agency's battle to stop what it says are anticompetitive reverse-payment settlements – commonly called pay-for-delay deals – between brand-name drug makers and their potential generic rivals.